'Faster to­geth­er': As­traZeneca breaks in­to clin­i­cal ser­vices busi­ness with new com­pa­ny launch, lin­ing up two CRO part­ners to start 

LON­DON — As­traZeneca has launched a new glob­al health tech busi­ness, Evi­no­va, af­ter see­ing a gap in the mar­ket to re­duce the time and cost of clin­i­cal tri­als while mak­ing the process eas­i­er for pa­tients.

Fi­nan­cial­ly backed by As­traZeneca but op­er­at­ing as a sep­a­rate busi­ness, Evi­no­va will pro­vide glob­al ser­vices to CROs and phar­ma com­pa­nies to de­sign, run and mon­i­tor clin­i­cal tri­als. Evi­no­va will charge cus­tomers for ac­cess to its tech, op­er­at­ing on a rev­enue-based mod­el.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER